Coronavirus Infection Clinical Trial
— ProCovOfficial title:
Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study (ProCov)
NCT number | NCT04344106 |
Other study ID # | 20202703-2 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2020 |
Est. completion date | May 1, 2020 |
The prone position consists of placing the patient on his or her stomach with the head on the side, during sessions lasting several hours a day and could help spontaneous ventilate the patient.
Status | Recruiting |
Enrollment | 25 |
Est. completion date | May 1, 2020 |
Est. primary completion date | April 15, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patient aged at least 18 years; - Hospitalized in a COVID unit or intensive care unit; - Spontaneously breathing and with oxygen therapy with nasal canula, mask or High Flow Oxygen Therapy; - Requiring oxygen therapy = 1l for Sat = 90%; - COVID 19 positive in RT-PCR or diagnosis on clinicals symptoms and highly evocatives scannographics lesions in an epidemic period; - Chest scanner without injection within 72 hours prior to inclusion; - Bilateral scannographic lesions, including posterior condensations and/or posterior predominance of lesions; - Patient benefiting from French social security, under any regime Exclusion Criteria: - acute respiratory distress (polypnea >25 or use of accessory respiratory muscles); - Alteration of consciousness; - Active or recent hemoptysis (<1 month); - Recent Thrombo-Embolic Venous Disease (< 1 month); - Pericardial effusion; - Pleural effusion of high abundance, clinical or scannographic; - Chronic back or cervical pain/ history of spinal surgery/ bone metastases; - Wounds, facial trauma, tracheal, sternal or facial surgery < 15 days; - Recent abdominal surgery (< 1 month); - Intracranial HyperTension > 30mmHg; - Patient deprived of liberty, under guardianship or curatorship; - Pregnant or lactating woman. |
Country | Name | City | State |
---|---|---|---|
France | CHI Aix-Pertuis | Aix-en-Provence |
Lead Sponsor | Collaborator |
---|---|
ELHARRAR Xavier |
France,
Ding L, Wang L, Ma W, He H. Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: a multi-center prospective cohort study. Crit Care. 2020 Jan 30;24(1):28. doi: 10.1186/s13054-020-2738-5. — View Citation
Gattinoni L, Taccone P, Carlesso E, Marini JJ. Prone position in acute respiratory distress syndrome. Rationale, indications, and limits. Am J Respir Crit Care Med. 2013 Dec 1;188(11):1286-93. doi: 10.1164/rccm.201308-1532CI. Review. — View Citation
Guérin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, Mercier E, Badet M, Mercat A, Baudin O, Clavel M, Chatellier D, Jaber S, Rosselli S, Mancebo J, Sirodot M, Hilbert G, Bengler C, Richecoeur J, Gainnier M, Bayle F, Bourdin G, Leray V, Girard R, Baboi L, Ayzac L; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013 Jun 6;368(23):2159-68. doi: 10.1056/NEJMoa1214103. Epub 2013 May 20. — View Citation
Munshi L, Del Sorbo L, Adhikari NKJ, Hodgson CL, Wunsch H, Meade MO, Uleryk E, Mancebo J, Pesenti A, Ranieri VM, Fan E. Prone Position for Acute Respiratory Distress Syndrome. A Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2017 Oct;14(Supplement_4):S280-S288. doi: 10.1513/AnnalsATS.201704-343OT. Review. — View Citation
Scaravilli V, Grasselli G, Castagna L, Zanella A, Isgrò S, Lucchini A, Patroniti N, Bellani G, Pesenti A. Prone positioning improves oxygenation in spontaneously breathing nonintubated patients with hypoxemic acute respiratory failure: A retrospective study. J Crit Care. 2015 Dec;30(6):1390-4. doi: 10.1016/j.jcrc.2015.07.008. Epub 2015 Jul 16. — View Citation
Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr;20(4):425-434. doi: 10.1016/S1473-3099(20)30086-4. Epub 2020 Feb 24. — View Citation
Sun Q, Qiu H, Huang M, Yang Y. Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province. Ann Intensive Care. 2020 Mar 18;10(1):33. doi: 10.1186/s13613-020-00650-2. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of "responder" patients to prone position | PaO2 improvement of more than 20% after one hour in prone position in spontaneously breathing non intubated COVID-19 patients. | 1 hour | |
Secondary | proportion of "persistent responders" patients after prone position | PaO2 improvement of more than 20% at 6 to 12 hours from return to supine position. | 1 day | |
Secondary | Evolution of PaO2 | PaO2 at 1 hour from the start of prone position and at 6 to 12 hours afterreturn to supine position. | 1 day | |
Secondary | Duration of prone positioning and PaO2 evolution | Look for an association between the time spent in Prone positione and persistent responder or not; | 2 days | |
Secondary | Evolution of Spo2 | proportion of patients improving their arterial saturation within 1 hour of Prone Position | 1 hour | |
Secondary | EVA Dyspnea | evolution of the EVA scores for dyspnea at 1 hour from the start of the Prone Position and at 6 hours after the end of the Prone Position | 1 day | |
Secondary | Intolerance to prone positioning | proportion of patients intolerant to prone position (Prone Position <1h); | 1 day | |
Secondary | Tolerance to prone positioning | proportion of patients who can maintain prone position for more than 3 h. | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04369456 -
Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients
|
N/A | |
Completed |
NCT04527471 -
Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19
|
Phase 2 | |
Recruiting |
NCT04410510 -
P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19
|
Phase 2/Phase 3 | |
Withdrawn |
NCT04383899 -
Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
|
||
Completed |
NCT04542915 -
COVID-19-Related Health and Practices Among Dental Hygienists
|
||
Not yet recruiting |
NCT04400019 -
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
|
Phase 2/Phase 3 | |
Terminated |
NCT04954014 -
Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
|
Phase 2 | |
Completed |
NCT04532632 -
Taste and Smell Impairment in Critically Ill COVID-19 Patients
|
||
Suspended |
NCT04385771 -
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
|
N/A | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Completed |
NCT04413435 -
Clinical Characteristics of Critically Ill Patients With COVID-19
|
||
Terminated |
NCT05593770 -
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
|
Phase 2/Phase 3 | |
Completed |
NCT04510493 -
Canakinumab in Patients With COVID-19 and Type 2 Diabetes
|
Phase 3 | |
Active, not recruiting |
NCT04587219 -
The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older
|
Phase 2 | |
Withdrawn |
NCT05430958 -
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04596579 -
SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
|
||
Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
Enrolling by invitation |
NCT04484025 -
SPI-1005 Treatment in Moderate COVID-19 Patients
|
Phase 2 | |
Terminated |
NCT04442230 -
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04642638 -
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
|
Phase 2/Phase 3 |